Raymond James Reiterates an 'Outperform' on Amgen (AMGN); DaVita Contract Revelation Indicates Near-Term Upside on EPO Pricing
Go back to Raymond James Reiterates an 'Outperform' on Amgen (AMGN); DaVita Contract Revelation Indicates Near-Term Upside on EPO Pricing| Amgen Inc (NASDAQ: AMGN) | Delayed: 419.38 +4.17 (1.00%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $415.21 | 52 Week High | $176.85 | |||
| Open | $412.98 | 52 Week Low | $133.64 | |||
| Day High | $419.60 | P/E | 63.16 | |||
| Day Low | $410.40 | EPS | $6.64 | |||
| Volume | 2,880,522 | |||||
| DaVita Inc. (NYSE: DVA) | Delayed: 176.70 -3.36 (1.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $180.06 | 52 Week High | $78.77 | |||
| Open | $177.97 | 52 Week Low | $55.00 | |||
| Day High | $180.00 | P/E | 61.14 | |||
| Day Low | $176.20 | EPS | $2.89 | |||
| Volume | 499,946 | |||||
